Conference · The Journal of Prevention of Alzheimer's Disease · 2021
Symposia — Oral Communications — Late Breaking News
This work set out to investigate whether a cluster of genetic variants at the 2q12 locus could predict how patients with mild Alzheimer's disease respond to piromelatine. It reported that this polymorphism cluster may predict patients' response to the treatment.
This work set out to investigate whether a cluster of genetic variants at the 2q12 locus could predict how patients with mild Alzheimer's disease respond to piromelatine. It reported that this polymorphism cluster may predict patients' response to the treatment.
Dante Labs’ involvement
Juan Caceres, Generoso Ianniciello and Mattia Capulli of Dante Labs are co-authors of this oral communication (OC10), alongside researchers from the University of Southern California and Neurim Pharmaceuticals.
Other publications
Peer-reviewed · Clinical Case Reports · 2026
Unveiling New Insights: Reinterpreting DES Mutation, p.Arg383His, Through a Study of an Iranian Family With Isolated Hypertrophic Cardiomyopathy, Implication for Phenotype–Genotype Correlation Analysis
Peer-reviewed · International Journal of Genomics · 2026
Alport Syndrome–Associated Pathogenic COL4A4 Variant in Sisters With Chronic Kidney Disease: Clinical Findings and Integrative Network Analysis
Peer-reviewed · Biology · 2026
Why Should a Genome Be Protected? Ethical, Legal, and Security Challenges in the Protection of Genomic Data
One test. A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. Physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Free shipping · Results in 6–8 weeks